基础医学与临床 ›› 2007, Vol. 27 ›› Issue (2): 206-209.
• 临床园地 • 上一篇 下一篇
李洁 曾学军
收稿日期:
修回日期:
出版日期:
发布日期:
通讯作者:
Received:
Revised:
Online:
Published:
摘要: 本文对抗CD20单克隆抗体,美罗华(Rituximab)治疗系统性红斑狼疮(SLE)免疫病理生理,临床疗效及不良反应进行分析总结。美罗华治疗近百例活动性SLE患者的结果显示,80%的SLE活动指数有明显下降,狼疮性肾炎得到临床缓解;90%的患者耐受性好。约10%的患者在输注美罗华期间有轻度过敏反应,个别患者发生严重的机会性感染。初步临床研究提示,美罗华治疗SLE是可行的,其疗效和安全性有待于大样本临床验证。
Abstract: To discuss the clinical efficacy,immunological consequences and adverse effects of anti-CD20 monoclonal antibody in systemic lupus erythematosus .A total of nearly 100 patients have been reported,and about 80% of them achieved marked reduction in global disease activity,clinical remission in lupus nephritis.Anti-CD20 monoclonal antibody was well tolerated in 90% of the patients,though10% of them had hypersensitivity reactions and 4 patients had severe infection.
李洁 曾学军. 抗CD20单克隆抗体治疗活动性系统性红斑狼疮[J]. 基础医学与临床, 2007, 27(2): 206-209.
. [J]. Basic & Clinical Medicine, 2007, 27(2): 206-209.
0 / / 推荐
导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks
链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/
http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2007/V27/I2/206